Telomir Pharmaceuticals, Inc. (TELO): who owns it and who trades it
As of Nov 16, 2026, no open-market insider purchases or sales of TELO were reported in the last 12 months. 1 of the 50 famous funds we follow held it at their last quarter end.
Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.
At a glance
Insider trades
No TELO insider reported an open-market purchase or sale in the last 12 months.
What this data shows, and what it doesn't
- Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
- Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
- "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
- Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
- Filings are self-reported and can be amended. Each trade links to its original filing. Methodology
TELO short interest
Low short interest. 1.1% of TELO shares are sold short: about 1 share in 92. Over the last 12 reports the number of shares short went down 28%.
As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.
As of Oct 30, 2026, 750,539 TELO shares were sold short, 1.1% of the shares outstanding, down 2.5% from the report before. At the average daily volume of 63,071 shares, buying them all back would take about 11.9 trading days (days to cover).
Shares short, % of all shares
Days to cover
Every report
| Settlement date | Shares short | % of shares | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|---|
| Oct 30, 2026 | 750,539 | 1.09% | -3% | 63,071 | 11.9 |
| Oct 15, 2026 | 769,992 | 1.12% | -7% | 192,595 | 4.0 |
| Sep 30, 2026 | 825,678 | 1.20% | +6% | 99,163 | 8.3 |
| Sep 15, 2026 | 777,078 | 1.13% | -5% | 39,441 | 19.7 |
| Aug 31, 2026 | 819,595 | 1.19% | +1% | 57,733 | 14.2 |
| Aug 14, 2026 | 813,874 | 1.18% | -16% | 50,077 | 16.2 |
| Jul 31, 2026 | 963,348 | 2.80% | -1% | 142,040 | 6.8 |
| Jul 15, 2026 | 974,290 | 2.83% | +2% | 52,972 | 18.4 |
| Jun 30, 2026 | 953,308 | 2.77% | +1% | 189,111 | 5.0 |
| Jun 15, 2026 | 942,330 | 2.74% | +2% | 93,623 | 10.1 |
| May 29, 2026 | 923,133 | 2.69% | -11% | 87,678 | 10.5 |
| May 15, 2026 | 1.04M | 3.03% | +2% | 101,160 | 10.3 |
Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks
Telomir Pharmaceuticals company events
Telomir Pharmaceuticals filed 22 reports on Form 8-K in the last 12 months, 5 of them about an important change (leadership, listing). The latest was on Oct 6, 2026.
- Oct 6, 2026AgreementTelomir Pharmaceuticals, Inc. entered into a securities purchase agreement with various investors, pursuant to which the Company agreed to issue and sell to the Investors in a private placement 4,843,300 shares of the Company’s common stock, no par value. Filing
- Sep 17, 2026AnnouncementShared information with investors. Filing
- Sep 16, 2026VoteReported shareholder vote results. Filing
- Sep 14, 2026AnnouncementShared information with investors. Filing
- Aug 10, 2026AnnouncementShared information with investors. Filing
- Jun 15, 2026AnnouncementShared information with investors. Filing
- Jun 8, 2026LeadershipAlan Weichselbaum will be no longer serving as the Chief Financial Officer of Telomir Pharmaceuticals, Inc. Filing
- May 20, 2026AnnouncementShared information with investors. Filing
- Apr 30, 2026AnnouncementTelomir Pharmaceuticals Announces FDA Clearance of IND for Telomir-Zn in Triple-Negative Breast Cancer Company Plans to Initiate First-in-Human Phase 1/2 Trial in 1H 2026, Anchored by a Leading U.S. Academic Medical Center Telomir Pharmaceuticals, Inc. announced that the U.S. Food and Drug… Filing
- Apr 24, 2026DealThe information contained in Item 1.01 above is incorporated herein. Filing
- Mar 31, 2026AnnouncementTelomir Pharmaceuticals, Inc. received a letter from the Nasdaq Capital Markets informing the Company that upon holding its 2025 Annual Meeting of Shareholders, the Company is now in compliance with Nasdaq Listing Rule 5620(a) and has determined the matter now closed. Filing
- Mar 31, 2026AnnouncementTelomir Pharmaceuticals Submits IND to FDA for Telomir-1 (Telomir-Zn) in Advanced and Metastatic Triple-Negative Breast Cancer First-in-class metal-modulating epigenetic therapy targeting iron-dependent pathways with preclinical efficacy and a favorable GLP safety profile. Filing
- Mar 27, 2026LeadershipAt the Annual Meeting of the Shareholders of Telomir Pharmaceuticals, Inc., the Company’s shareholders approved an amendment to the Company’s 2023 Omnibus Incentive Plan to (1) increase the number of shares reserved under the Plan from 6,500,000 to 11,500,000, and (2) to allow for the repricing of… Filing
- Feb 17, 2026AnnouncementTelomir Pharmaceuticals Demonstrates Broad Tumor Cell Mortality in Human Triple-Negative Breast Cancer Models Iron-rescue experiments confirm tumor cell mortality is mechanistically driven, not nonspecific cytotoxicity. Filing
- Feb 5, 2026AnnouncementTelomir Pharmaceuticals Reports New Cellular Data Supporting an Epigenetic Modulation Mechanism Implicated in Cancer and Aging Cellular findings show Telomir-Zn modulates intracellular metal balance linked to oxidative stress, mitochondrial dysfunction, DNA methylation instability, and genomic… Filing
- Jan 12, 2026ListingTelomir Pharmaceuticals, Inc. submitted its preliminary proxy statement on Schedule 14A to the Securities and Exchange Commission in connection with its annual meeting of shareholders. Filing
- Jan 5, 2026AnnouncementTelomir Pharmaceuticals Announces Telomir-1 Significantly Reduced Tumor Growth and Metastases in Aggressive Triple-Negative Breast Cancer Animal Models Telomir Pharmaceuticals, Inc. (NASDAQ: TELO) is reporting results from a completed preclinical efficacy study evaluating Telomir-1 (Zn-Telomir) in… Filing
- Dec 22, 2025LeadershipThe Compensation Committee of the Board of Directors of Telomir Pharmaceuticals, Inc. approved certain short-term and long-term incentive actions for the Company’s Chief Executive Officer, Erez Aminov. Filing
- Dec 17, 2025AnnouncementTelomir Pharmaceuticals Reports Favorable IND-Enabling GLP Safety Results for Telomir-1 Supporting First-in-Human Clinical Development The completion of IND-enabling GLP safety studies represents a key milestone in the Company’s ongoing clinical development strategy for Telomir-1. Filing
- Nov 24, 2025AnnouncementTelomir Pharmaceuticals Reports New Data Showing Telomir-1 Significantly Reduces PSA Levels in Human Prostate Cancer Cells PSA is a validated FDA-recognized clinical endpoint in assessing prostate cancer treatment response; Telomir-1 lowered PSA levels in a dose-related manner. Filing
- Nov 20, 2025LeadershipDeparture of Directors or Certain Officers. Filing
- Nov 20, 2025AnnouncementTelomir Pharmaceuticals Announces Telomir-1 Kills Aggressive Human Leukemia Cells The findings expand Telomir-1’s oncology profile into cancers of the blood, adding to previously reported activity in triple-negative breast, pancreatic, and aggressive prostate cancer models. Filing
From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week
Telomir Pharmaceuticals financials
Famous investors that hold TELO
1 of the 50 well-known investors we track reported holding TELO in their latest 13F filing. The largest position is Ken Griffin's, worth $176K.
| Fund | Quarter | Shares | Value | Of portfolio | Change |
|---|---|---|---|---|---|
| Ken Griffin · Citadel Advisors | Q3 2026 | 146,425 | $176K | 0.0% | +1004% |
From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.
Questions about Telomir Pharmaceuticals, Inc. (TELO) stock
Are TELO insiders buying or selling?
No TELO insider reported an open-market purchase or sale on Form 4 in the last 12 months. Share awards, option exercises and gifts are not counted.
What is the short interest in TELO?
As of Oct 30, 2026, 750,539 TELO shares were sold short, 1.1% of the shares outstanding, down 2.5% from the report before. At the average daily volume of 63,071 shares, buying them all back would take about 11.9 trading days (days to cover). See the history.
Which famous investors hold TELO?
1 of the 50 well-known investors we track reported TELO in their latest 13F filing, including Ken Griffin. The largest position is worth $176K. See all holders.
Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.